Habib Dable joins Tyra Biosciences (NASDAQ: TYRA) board as Class II director

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did Tyra Biosciences (TYRA) announce about its board of directors?

Who is Habib J. Dable, the new director at Tyra Biosciences (TYRA)?

What equity compensation did Habib J. Dable receive from Tyra Biosciences (TYRA)?

How will Habib J. Dable’s stock options at Tyra Biosciences (TYRA) vest?

Is Habib J. Dable considered an independent director at Tyra Biosciences (TYRA)?

What other compensation and protections does Habib J. Dable receive from Tyra Biosciences (TYRA)?

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

8-K

Tyra Biosciences, Inc. expanded its board of directors from nine to ten members and appointed Habib J. Dable as a Class II director, with his initial term ending at the company’s 2026 annual meeting of stockholders. The board determined he qualifies as an independent director under Nasdaq rules.

In connection with his appointment, Dable received options to purchase 44,400 shares of Tyra’s common stock at the fair market value on the grant date, vesting in equal monthly installments over 36 months. He will also receive cash compensation under the company’s Non-Employee Director Compensation Program and has entered into Tyra’s standard indemnification agreement.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Board size after change: 10 directors Previous board size: 9 directors Stock options granted: 44,400 shares +2 more

5 metrics

Board size after change 10 directors Board increased from nine to ten members

Previous board size 9 directors Number of authorized directors before increase

Stock options granted 44,400 shares Options granted to Habib J. Dable upon board appointment

Vesting period 36 months Monthly vesting schedule for Dable’s stock options

Director age 56 years Age of Habib J. Dable at time of appointment

Class II director, Non-Employee Director Compensation Program, indemnification agreement, independent director, +1 more

5 terms

Class II director financial

"appointed Habib J. Dable to the Board as a Class II director with an initial term"

A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.

Non-Employee Director Compensation Program financial

"pursuant to the Company’s Non-Employee Director Compensation Program, Mr. Dable was granted options"

indemnification agreement regulatory

"Mr. Dable entered into the Company’s standard form of indemnification agreement"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

independent director regulatory

"The Board has determined that Mr. Dable is an independent director in accordance with the listing requirements"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Nasdaq Global Select Market financial

"Common Stock, par value $0.0001 per share | | TYRA | | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Understanding 8-K Material Events →

04/17/2026 - 08:02 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2026

Tyra Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-40800

83-1476348

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


2656 State Street
Carlsbad, California		92008
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 728-4760

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	TYRA	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine to ten and appointed Habib J. Dable to the Board as a Class II director with an initial term expiring at the Company’s 2026 annual meeting of stockholders.

Mr. Dable, 56, has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022. Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021. Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable has served as a member of the board of directors of Spyglass Pharma, Inc. since February 2026, Relay Therapeutics, Inc. since November 2025, Day One Biopharmaceuticals, Inc. since January 2024, and PepGen Inc. since September 2022, and he previously served as a member of the board of directors of Millendo Therapeutics, Inc. from September 2018 until January 2021, Blueprint Medicines Corporation (which was subsequently acquired by Sanofi S.A.) from June 2022 to July 2025, Aerovate Therapeutics, Inc. from July 2023 to April 2025, and Albireo Pharma, Inc. (which was subsequently acquired by Ipsen Biopharmaceuticals, Inc.) from August 2022 to March 2023. Mr. Dable holds a bachelor’s degree in business administration and an MBA, each from the University of New Brunswick in Canada.

In connection with his appointment to the Board, pursuant to the Company’s Non-Employee Director Compensation Program, Mr. Dable was granted options to purchase 44,400 shares of the Company’s common stock. The options have an exercise price per share equal to the fair market value of the Company’s common stock on the date of grant. The foregoing awards will vest in substantially equal monthly installments over the thirty-six months following the date of grant. Mr. Dable will also receive cash compensation for his service on the Board and committees thereof in accordance with the Company’s Non-Employee Director Compensation Program, as such program may be amended from time to time. Further, in connection with his appointment to the Board, Mr. Dable entered into the Company’s standard form of indemnification agreement, the form of which has been filed with the Company’s most recent annual report on Form 10-K.

There are no arrangements or understandings between Mr. Dable and any other person pursuant to which he was selected to serve on the Board. There are no transactions in which the Company or any of its subsidiaries is a party and in which Mr. Dable has a material interest subject to disclosure under Item 404(a) of Regulation S-K. The Board has determined that Mr. Dable is an independent director in accordance with the listing requirements of The Nasdaq Stock Market LLC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Tyra Biosciences expanded its board from nine to ten directors and appointed Habib J. Dable as a Class II director. His initial term runs until the company’s 2026 annual meeting of stockholders, increasing the board’s size while adding additional industry experience.

Habib J. Dable is a 56-year-old biopharmaceutical executive and advisor at RA Capital Management. He previously served as President and CEO of Acceleron Pharma and held senior leadership roles at Bayer, including President of U.S. Pharmaceuticals and Global Head of Specialty Medicine.

In connection with joining the board, Habib J. Dable received options to purchase 44,400 shares of Tyra Biosciences common stock. The options are priced at the fair market value on the grant date and vest in substantially equal monthly installments over 36 months.

Habib J. Dable’s options to buy 44,400 Tyra Biosciences shares will vest in substantially equal monthly installments. The vesting period runs over 36 months following the grant date, aligning his equity compensation with multi-year board service and ongoing company performance.

Yes. The board of Tyra Biosciences determined that Habib J. Dable qualifies as an independent director. This determination was made in accordance with the listing requirements of The Nasdaq Stock Market LLC, supporting standard governance and independence practices for the company’s board.

Beyond stock options, Habib J. Dable will receive cash compensation under Tyra’s Non-Employee Director Compensation Program. He also entered into the company’s standard indemnification agreement, which offers legal protection for his board service as previously filed with Tyra’s annual report on Form 10-K.

TYRA BIOSCIENCES, INC.

Date: April 17, 2026

/s/ Alan Fuhrman

Alan Fuhrman

Chief Financial Officer

3 documents